FDA warns Novo Nordisk over unreported potential Ozempic side effects
The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.
Watch CBS News
The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.
The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month in some cases, officials said.
A one-month supply of Ozempic and Wegovy will now cost $499 out of pocket for Costco shoppers.
Do weight loss drug labels warn enough about potential side effects? A patient who needed emergency surgery is suing prescription drugmaker Novo Nordisk.
A group of weight loss and diabetes treatment drugs, known as GLP-1 agonists, work by curbing appetite centers in the brain. But animal studies suggest these drugs could also potentially reduce addiction to nicotine, alcohol, and opioids. Dr. Jon LaPook explains.
Semaglutide, the active ingredient in drugs like Wegovy and Ozempic, can help people lose weight — and a new study says it may also help people quit smoking.
Novo Nordisk and Lilly can't keep up with demand for their weight loss drugs such as Ozempic, Wegovy and Mounjaro. But they object to specialty pharmacies making their own cheaper versions to fill the gap — providing as much as 30% of those drugs sold in the U.S.
With weight loss drugs Ozempic and Wegovy in short supply, a startup is offering their own version that has yet to be approved by the FDA, raising concerns from a Stanford doctor. Nancy Chen reports. Website: http://kpix.com/ YouTube: http://www.youtube.com/CBSSanFrancisco Facebook: https://www.facebook.com/CBSSanFrancisco Instagram: https://www.instagram.com/kpixtv/ Twitter: https://twitter.com/KPIXtv
Anna Werner reports on an investigation into dozens of TikTok profiles offering to sell the prescription weight loss drugs at lower prices that were almost all scams.
GLP-1 class medications reduce cardiovascular risk and treat diabetes. But they also allow people to lose an average of 10-20 percent of their body weight in the first year. What does that mean for the overweight or obese?
Ozempic and other GLP-1 RA drugs, including Wegovy, Mounjaro and Zepbound, are being scrutinized.
From the Ozempic "ripple effect" to health tech and more, experts share their predictions for 2024 wellness trends.
The FDA and drugmaker Novo Nordisk are working to identify thousands of counterfeit Ozempic drugs seized in an ongoing investigation.
WeightWatchers program aims to help members maintain healthy habits while taking anti-obesity drugs like Ozempic and Wegovy.
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
The warning about scams comes as sales have boomed for Ozempic, Wegovy and other drugs used for weight loss.
